Read by QxMD icon Read


Giorgio Bogani, Elena Tagliabue, Mauro Signorelli, Antonino Ditto, Fabio Martinelli, Valentina Chiappa, Lavinia Mosca, Ilaria Sabatucci, Umberto Leone Roberti Maggiore, Domenica Lorusso, Francesco Raspagliesi
OBJECTIVE: To test the applicability of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC). METHODS: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynäkologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied...
February 23, 2018: Journal of Gynecologic Oncology
A M Dueckelmann, D Fink, P Harter, V Heinzelmann, C Marth, M Mueller, A Reinthaller, K Tamussino, P Wimberger, J Sehouli
The title of the article has been published incorrectly. The correct title is given below.
February 14, 2018: Archives of Gynecology and Obstetrics
Zhigang Jin, Ning Wang, Yishan Su, Qiuling Yang
Underwater acoustic sensor networks (UASNs) have become a hot research topic. In UASNs, nodes can be affected by ocean currents and external forces, which could result in sudden link disruption. Therefore, designing a flexible and efficient link disruption restoration mechanism to ensure the network connectivity is a challenge. In the paper, we propose a glider-assisted restoration mechanism which includes link disruption recognition and related link restoring mechanism. In the link disruption recognition mechanism, the cluster heads collect the link disruption information and then schedule gliders acting as relay nodes to restore the disrupted link...
February 7, 2018: Sensors
A M Dueckelmann, D Fink, P Harter, V Heinzelmann, C Marth, M Mueller, A Reinthaller, K Tamussino, P Wimberger, J Sehouli
BACKGROUND: Ovarian, tubal, and peritoneal carcinomas primarily affect the peritoneal cavity, and they are typically diagnosed at an advanced tumor stage (Foley, Rauh-Hain, del Carmen in Oncology (Williston Park) 27:288-294, 2013). In the course of primary surgery, postoperative tumor residuals are, apart from the tumor stage, the strongest independent factors of prognosis (du Bois, Reuss, Pujade-Lauraine, Harter, Ray-Coquard, Pfisterer in Cancer 115:1234-1244, 2009). Due to improved surgical techniques, including the use of multi-visceral procedures, macroscopic tumor clearance can be achieved in oncological centers, in most cases (Harter, Muallem, Buhrmann et al in Gynecol Oncol 121:615-619, 2011)...
April 2018: Archives of Gynecology and Obstetrics
Mohammad M Pourseif, Gholamali Moghaddam, Behrouz Naghili, Nazli Saeedi, Sepideh Parvizpour, Ahmad Nematollahi, Yadollah Omidi
EG95 oncospheral antigen plays a crucial role in Echinococcus granulosus pathogenicity. Considering the diversity of antigen among different EG95 isolates, it seems to be an ideal antigen for designing a universal multivalent minigene vaccine, so-called multi-epitope vaccine. This is the first in silico study to design a construct for the development of global EG95-based hydatid vaccine against E. granulosus in intermediate hosts. After antigen sequence selection, the three-dimensional structure of EG95 was modeled and multilaterally validated...
February 2018: Computational Biology and Chemistry
Annett Kahl, Andreas du Bois, Philipp Harter, Sonia Prader, Stephanie Schneider, Florian Heitz, Alexander Traut, Pier Francesco Alesina, Beate Meier, Martin Walz, Annettte Brueckner, Harald-Thomas Groeben, Violeta Brunkhorst, Sebastian Heikaus, Beyhan Ataseven
BACKGROUND: We evaluated the prognostic impact of the age-adjusted Charlson Comorbidity Index (ACCI) on both postoperative morbidity and overall survival (OS) in patients with advanced epithelial ovarian cancer (EOC) treated at a tertiary gynecologic cancer center. PATIENTS AND METHODS: Exploratory analysis of our prospectively documented tumor registry was performed. Data of all consecutive patients with stage IIIB-IV ovarian cancer who underwent primary cytoreductive surgery (PDS) from January 2000 to June 2016 were analyzed...
November 2017: Annals of Surgical Oncology
Nathalie Arians, Meinhard Kieser, Laura Benner, Nathalie Rochet, Sonja Katayama, Florian Sterzing, Klaus Herfarth, Kai Schubert, Lars Schröder, Christina Leitzen, Andreas Schneeweiss, Christof Sohn, Jürgen Debus, Katja Lindel
PURPOSE: To assess treatment tolerance and toxicity rates of consolidative whole-abdominal radiation therapy (WART) following cytoreductive surgery and carboplatin/paclitaxel chemotherapy in high-risk patients with advanced ovarian cancer (International Federation of Gynecology and Obstetrics stage III) using intensity modulated radiation therapy. METHODS AND MATERIALS: The OVAR-IMRT-02 study is a multicenter, single-arm, phase 2 trial. Twenty patients with optimally debulked ovarian cancer (International Federation of Gynecology and Obstetrics stage III) with complete remission after chemotherapy were treated with intensity modulated WART as a consolidation therapy...
November 15, 2017: International Journal of Radiation Oncology, Biology, Physics
Takuya Moriyama, Yuichi Shiraishi, Kenichi Chiba, Rui Yamaguchi, Seiya Imoto, Satoru Miyano
Detection of somatic mutations from tumor and matched normal sequencing data has become a standard approach in cancer research. Although a number of mutation callers have been developed, it is still difficult to detect mutations with low allele frequency even in exome sequencing. We expect that overlapping paired-end read information is effective for this purpose, but no mutation caller has modeled overlapping information statistically in a proper form in exome sequence data. Here, we develop a Bayesian hierarchical method, OVar- Call (https://github...
March 1, 2017: IEEE Transactions on Nanobioscience
G R Gowane, Najif Akram, L L L Prince, Ved Prakash, Arun Kumar
India harbors a vast diversity of sheep (40 breeds). The study was carried out to assess the genetic diversity of DRB1 and DQA2 locus of the ovar-MHC and their possible association with Peste des petits ruminants (PPR) virus vaccine response in Malpura and Avikalin sheep breeds maintained at an organized institute flock in the semi-arid region of India. Genetic analysis revealed the rich diversity of DRB1 locus with 23 alleles in Malpura and 21 alleles in Avikalin sheep that included 9 new alleles. DQA2 locus also had rich diversity with 19 alleles in Malpura and 20 alleles in Avikalin sheep that included 7 new alleles...
October 2, 2017: Animal Biotechnology
Samantha B Douglas, Gilles Clément, Pierre Denise, Scott J Wood
Constant velocity Off-Vertical Axis Rotation (OVAR) imposes a continuously varying orientation of the head and body relative to gravity, which generates a modulation of horizontal (conjugate and vergence), vertical, and torsional eye movements. We introduced the head-turn-on-trunk paradigm during OVAR to examine the extent to whether the modulation of these ocular reflexes is mediated by graviceptors in the head, i.e., otoliths, versus other body graviceptors. Ten human subjects were rotated in darkness about their longitudinal axis 20° off-vertical at a constant velocity of 45 and 180°/s, corresponding to 0...
February 8, 2017: Scientific Reports
David J Pulford, Philipp Harter, Anne Floquet, Catherine Barrett, Dong Hoon Suh, Michael Friedlander, José Angel Arranz, Kosei Hasegawa, Hiroomi Tada, Peter Vuylsteke, Mansoor R Mirza, Nicoletta Donadello, Giovanni Scambia, Toby Johnson, Charles Cox, John K Chan, Martin Imhof, Thomas J Herzog, Paula Calvert, Pauline Wimberger, Dominique Berton-Rigaud, Myong Cheol Lim, Gabriele Elser, Chun-Fang Xu, Andreas du Bois
BACKGROUND: The focus on translational research in clinical trials has the potential to generate clinically relevant genetic data that could have importance to patients. This raises challenging questions about communicating relevant genetic research results to individual patients. METHODS: An exploratory pharmacogenetic analysis was conducted in the international ovarian cancer phase III trial, AGO-OVAR 16, which found that patients with clinically important germ-line BRCA1/2 mutations had improved progression-free survival prognosis...
October 21, 2016: BMC Medical Ethics
Mehmet Ulas Cinar, Michelle R Mousel, Lynn M Herrmann-Hoesing, J Bret Taylor, Stephen N White
BACKGROUND: The major histocompatibility complex (MHC) is an organized cluster of tightly linked vertebrate genes with immunological and non-immunological functions. While the important MHC gene DRB1 has been examined in regard to many sheep infectious disease traits, only one study, based on microsatellite markers, has previously examined DRB1 and sheep production traits. Furthermore, to our knowledge no studies have examined DRB1 relationship with lifetime ewe prolificacy traits. Therefore, we analyzed association between the presence of DRB1 SNP haplotypes with internationally recognized standard names and production traits including growth and lifetime prolificacy in 370 Rambouillet, Columbia, and Polypay sheep...
December 31, 2016: Gene
Angela Sacchinelli, Roberta Venturella, Daniela Lico, Annalisa Di Cello, Antonella Lucia, Erika Rania, Roberto Cirillo, Fulvio Zullo
[This corrects the article DOI: 10.1155/2014/141020.].
2016: Obstetrics and Gynecology International
M Klar, A Hasenburg, M Hasanov, F Hilpert, W Meier, J Pfisterer, E Pujade-Lauraine, J Herrstedt, A Reuss, A du Bois
OBJECTIVES: We evaluated in a large study meta-database of prospectively randomised phase III trials the prognostic factors for progression-free survival (PFS) and overall survival (OS) in patients < and >40 years of age with advanced epithelial ovarian cancer. METHODS: A total of 5055 patients of the AGO, GINECO, NSGO intergroup studies AGO-OVAR 3, 5, 7 and 9 were merged to identify 294 patients <40 years and 4761 patients ≥40 years. We conducted survival analyses and Cox proportional hazard regression models and additionally analysed a very homogeneous subcohort of 405 patients with serous epithelial ovarian cancer, excellent performance status, who had received complete macroscopic upfront cytoreduction and ≥5 chemotherapy cycles...
October 2016: European Journal of Cancer
Gretchen H Roffler, Stephen J Amish, Seth Smith, Ted Cosart, Marty Kardos, Michael K Schwartz, Gordon Luikart
Identification of genes underlying genomic signatures of natural selection is key to understanding adaptation to local conditions. We used targeted resequencing to identify SNP markers in 5321 candidate adaptive genes associated with known immunological, metabolic and growth functions in ovids and other ungulates. We selectively targeted 8161 exons in protein-coding and nearby 5' and 3' untranslated regions of chosen candidate genes. Targeted sequences were taken from bighorn sheep (Ovis canadensis) exon capture data and directly from the domestic sheep genome (Ovis aries v...
September 2016: Molecular Ecology Resources
Christian Kurzeder, Isabel Bover, Frederik Marmé, Joern Rau, Patricia Pautier, Nicoletta Colombo, Domenica Lorusso, Petronella Ottevanger, Maria Bjurberg, Christian Marth, Pilar Barretina-Ginesta, Ignace Vergote, Anne Floquet, Josep M Del Campo, Sven Mahner, Lydie Bastière-Truchot, Nicolas Martin, Mikkel Z Oestergaard, Astrid Kiermaier, Carmen Schade-Brittinger, Sandra Polleis, Andreas du Bois, Antonio Gonzalez-Martin
PURPOSE: The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the primary efficacy analysis. PATIENTS AND METHODS: Eligible patients had ovarian carcinoma that progressed during or within 6 months of completing four or more platinum cycles, centrally tested low tumor HER3 mRNA expression (concentration ratio ≤ 2...
July 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
P Harter, A du Bois, S Mahner, J Pfisterer, O Ortmann, C Marth, D Fink, F Hilpert, U Wagner, J Sehouli
The AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.
February 2016: Geburtshilfe und Frauenheilkunde
Seyed Mohammad Ghoreyshi, Alireza Shahrabi, Tuleen Boutaleb
Increasing attention has recently been devoted to underwater sensor networks (UWSNs) because of their capabilities in the ocean monitoring and resource discovery. UWSNs are faced with different challenges, the most notable of which is perhaps how to efficiently deliver packets taking into account all of the constraints of the available acoustic communication channel. The opportunistic routing provides a reliable solution with the aid of intermediate nodes' collaboration to relay a packet toward the destination...
2016: Sensors
Gilles Clément, Scott J Wood
Two characteristics of otolith-ocular responses - linear vestibulo-ocular reflex and vergence - were examined during constant velocity off-vertical axis rotation (OVAR) in the dark. Sixteen subjects were rotated about their longitudinal axis when tilted 30° relative to the direction of gravity. Rotational velocities were 36 and 288/s corresponding to frequencies of 0.1 and 0.8Hz, respectively. Subjects were asked to imagine stationary targets located at 0.5m, 1m, and 2m in the straight-ahead direction. Binocular eye movements were recorded in the dark using infrared videography...
March 11, 2016: Neuroscience Letters
Philipp Harter, Toby Johnson, Dominique Berton-Rigaud, Sang-Yoon Park, Michael Friedlander, Josep M Del Campo, Muneaki Shimada, Frédéric Forget, Mansoor R Mirza, Nicoletta Colombo, Claudio Zamagni, John K Chan, Martin Imhof, Thomas J Herzog, Dearbhaile O'Donnell, Florian Heitz, Karen King, Sandy Stinnett, Catherine Barrett, Minesh Jobanputra, Chun-Fang Xu, Andreas du Bois
OBJECTIVE: AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the effect of clinically important germline BRCA1 and BRCA2 mutations on PFS. METHODS: Of 940 AGO-OVAR 16 participants, 664 had BRCA1/2 exon sequencing data (pazopanib, n=335; placebo, n=329). A Cox model was used to test the association between genetic variants and PFS...
March 2016: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"